

28 - References

References

692 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 6 References

1. Katona C, et al. Impact of screening old people with physical illness for depression? *Lancet* 2000; 356:91-92.
2. Lyketsos CG. Depression and diabetes: more on what the relationship might be. *Am J Psychiatry* 2010; 167:496-497.
3. Gallo JJ, et al. Long term effect of depression care management on mortality in older adults: follow-up of cluster randomized clinical trial in primary care. *BMJ* 2013; 346:f2570.
4. Naghavi M. Global, regional, and national burden of suicide mortality 1990 to 2016: systematic analysis for the Global Burden of Disease Study 2016. *BMJ* 2019; 364:l94.
5. Ryan J, et al. Late-life depression and mortality: influence of gender and antidepressant use. *Br J Psychiatry* 2008; 192:12-18.
6. Gutmiedl K, et al. How well do elderly patients with major depressive disorder respond to antidepressants: a systematic review and single- group meta-analysis. *BMC Psychiatry* 2020; 20:102.
7. Cipriani A, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet* 2018; 391:1357-1366.
8. Paykel ES, et al. Residual symptoms after partial remission: an important outcome in depression. *Psychol Med* 1995; 25:1171-1180.
9. Iosifescu DV, et al. Brain white-matter hyperintensities and treatment outcome in major depressive disorder. *Br J Psychiatry* 2006; 188:180-185.
10. Brown PJ, et al. Biological age, not chronological age, is associated with late-life depression. *J Gerontol A Biol Sci Med Sci* 2018; 73:1370-1376.
11. Tunvirachaisakul C, et al. Predictors of treatment outcome in depression in later life: a systematic review and meta-analysis. *J Affect Disord* 2018; 227:164-182.
12. Zilcha-Mano S, et al. Early symptom trajectories as predictors of treatment outcome for citalopram versus placebo. *Am J Geriatr Psychiatry* 2017; 25:654-661.
13. Mulsant BH, et al. What is the optimal duration of a short-term antidepressant trial when treating geriatric depression? *J Clin Psychopharmacol* 2006; 26:113-120.
14. Mottram P, et al. Antidepressants for depressed elderly. *Cochrane Database Syst Rev* 2006; 1:CD003491.
15. Hsu CW, et al. Comparative effectiveness of antidepressants on geriatric depression: real-world evidence from a population-based study. *J Affect Disord* 2022; 296:609-615.

16. National Institute for Health and Care Excellence. Depression in adults: treatment and management. NICE Guideline [NG222]. 2022 (last accessed December 2023); <https://www.nice.org.uk/guidance/ng222>.
17. Lenze EJ, et al. Antidepressant augmentation versus switch in treatment-resistant geriatric depression. *N Engl J Med* 2023; 388:1067–1079.
18. Krause M, et al. Efficacy and tolerability of pharmacological and non-pharmacological interventions in older patients with major depressive disorder: a systematic review, pairwise and network meta-analysis. *Eur Neuropsychopharmacol* 2019; 29:1003–1022.
19. Flint AJ, et al. Recurrence of first-episode geriatric depression after discontinuation of maintenance antidepressants. *Am J Psychiatry* 1999; 156:943–945.
20. Reynolds CF, III, et al. Maintenance treatment of major depression in old age. *N Engl J Med* 2006; 354:1130–1138.
21. Horowitz MA, et al. Distinguishing relapse from antidepressant withdrawal: clinical practice and antidepressant discontinuation studies. *BJPsych Advances* 2022; 28:297–311.
22. Romdhani A, et al. Discontinuation of antidepressants in older adults: a literature review. *Ther Clin Risk Manag* 2023; 19:291–299.
23. Smoller JW, et al. Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women’s Health Initiative study. *Arch Intern Med* 2009; 169:2128–2139.
24. Laporte S, et al. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies. *Pharmacol Res* 2017; 118:19–32.
25. Ön BI, et al. Antidepressant use and stroke or mortality risk in the elderly. *Eur J Neurol* 2022; 29:469–477.
26. Coupland C, et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. *BMJ* 2011; 343:d4551.
27. Haddad YK, et al. A comparative analysis of selective serotonin reuptake inhibitors and fall risk in older adults. *J Am Geriatr Soc* 2022; 70:1450–1460.
28. Williams LJ, et al. Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. *Int Clin Psychopharmacol* 2008; 23:84–87.
29. Power C, et al. Bones of contention: a comprehensive literature review of non-SSRI antidepressant use and bone health. *J Geriatr Psychiatry Neurol* 2019; 33:340–352.
30. Fagiolini A, et al. Rediscovering trazodone for the treatment of major depressive disorder. *CNS Drugs* 2012; 26:1033–1049.
31. Fagiolini A, et al. Trazodone in the management of major depression among elderly patients with dementia: a narrative review and clinical insights. *Neuropsychiatr Dis Treat* 2023; 19:2817–2831.
32. Heun R, et al. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study. *J Clin Psychiatry* 2013; 74:587–594.
33. Laux G. The antidepressant efficacy of agomelatine in daily practice: Results of the non-interventional study VIVALDI. *Eur Psychiatry* 2011; 26 Suppl 1:647.
34. Katona C, et al. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. *Int Clin Psychopharmacol* 2012; 27:215–223.
35. Bae JH, et al. Systematic review and meta-analysis of omega-3-fatty acids in elderly patients with depression. *Nutr Res* 2018; 50:1–9.

36. Hsu TW, et al. The efficacy and tolerability of memantine for depressive symptoms in major mental diseases: a systematic review and updated meta-analysis of double-blind randomized controlled trials. *J Affect Disord* 2022; 306:182-189.

Prescribing in older people CHAPTER 6

37. Smith KR, et al. Methylphenidate use in geriatric depression: a systematic review. *Int J Geriatr Psychiatry* 2021; 36:1304-1312.

38. Ochs-Ross R, et al. Comparison of long-term efficacy and safety of esketamine nasal spray plus oral antidepressant in younger versus older patients with treatment-resistant depression: post-hoc analysis of SUSTAIN-2, a long-term open-label phase 3 safety and efficacy study. *Am J Geriatr Psychiatry* 2022; 30:541-556.

39. Subramanian S, et al. Ketamine for depression in older adults. *Am J Geriatr Psychiatry* 2021; 29:914-916.

40. Moraros J, et al. The association of antidepressant drug usage with cognitive impairment or dementia, including Alzheimer disease: a systematic review and meta-analysis. *Depress Anxiety* 2017; 34:217-226.

41. Leng Y, et al. Antidepressant use and cognitive outcomes in very old women. *J Gerontol A Biol Sci Med Sci* 2018; 73:1390-1395.

42. Chan JYC, et al. Depression and antidepressants as potential risk factors in dementia: a systematic review and meta-analysis of 18 longitudinal studies. *J Am Med Dir Assoc* 2019; 20:279-286.e271.

43. Carriere I, et al. Antidepressant use and cognitive decline in community-dwelling elderly people - the Three-City Cohort. *BMC Med* 2017; 15:81.

44. Wang YC, et al. Increased risk of dementia in patients with antidepressants: a meta-analysis of observational studies. *Behav Neurol* 2018; 2018:5315098.

45. Watt JA, et al. Comparative efficacy of interventions for reducing symptoms of depression in people with dementia: systematic review and network meta-analysis. *BMJ* 2021; 372:n532.

46. Jeong HW, et al. Vortioxetine treatment for depression in Alzheimer's disease: a randomized, double-blind, placebo-controlled study. *Clin Psychopharmacol Neurosci* 2022; 20:311-319.

47. Leong C. Antidepressants for depression in patients with dementia: a review of the literature. *Consult Pharm* 2014; 29:254-263.

48. Costello H, et al. Antidepressant medications in dementia: evidence and potential mechanisms of treatment-resistance. *Psychol Med* 2023; 53:654-667.

49. Jin B, et al. Comparative efficacy and acceptability of treatments for depressive symptoms in cognitive impairment: a systematic review and Bayesian network meta-analysis. *Front Aging Neurosci* 2022; 14:1037414.

50. Draper B, et al. Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly. *Drugs Aging* 2008; 25:501-519.

51. Bose A, et al. Escitalopram in the acute treatment of depressed patients aged 60 years or older. *Am J Geriatr Psychiatry* 2008; 16:14-20.

52. Deidda A, et al. Interstitial lung disease induced by fluoxetine: systematic review of literature and analysis of Vigibase, Eudravigilance and a national pharmacovigilance database. *Pharmacol Res* 2017; 120:294-301.

53. Rosenberg T, et al. The relationship of SSRI and SNRI usage with interstitial lung disease and bronchiectasis in an elderly population: a case-control study. *Clin Interv Aging* 2017; 12:1977-1984.

54. Raskin J, et al. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder. *J Clin Psychopharmacol* 2008; 28:32-38.

55. Johnson EM, et al. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. *Am J Geriatr Psychiatry* 2006; 14:796-802.

56. Gonçalo AMG, et al. The effects of trazodone on human cognition: a systematic review. *Eur J Clin Pharmacol* 2021; 77:1623-1637.

Revision #1

Created 2026-01-04 20:17:03 UTC by Omar Ayman

Updated 2026-01-04 20:17:03 UTC by Omar Ayman